Goldman Sachs Reinstates Buy on Krystal Biotech, Announces $441 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 54.8%

Neg 0% Neu 54.8% Pos 0%

Goldman Sachs analyst Andrea Newkirk reinstates Krystal Biotech (NASDAQ:KRYS) with a Buy and announces $441 price target.